[go: up one dir, main page]

AR064389A1 - Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen. - Google Patents

Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.

Info

Publication number
AR064389A1
AR064389A1 ARP070105664A ARP070105664A AR064389A1 AR 064389 A1 AR064389 A1 AR 064389A1 AR P070105664 A ARP070105664 A AR P070105664A AR P070105664 A ARP070105664 A AR P070105664A AR 064389 A1 AR064389 A1 AR 064389A1
Authority
AR
Argentina
Prior art keywords
present
och3
alkyl
co2ch2ch3
ch2ch3
Prior art date
Application number
ARP070105664A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR064389A1 publication Critical patent/AR064389A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1), o una sal o solvato farmacéuticamente aceptable, en el que: R1, R3 y R4 son independientemente H, F, CI, -CHF2, -CF3, -OH, -CH2OH, -CH2CH2OH, -C:::N, -CH2C:::N, -CH2CH2C:::N, alquilo C1-5, -C(O)OR16, - NC(O)R16, -NSO2R16, -C(O)R16 o -OCH3; R2 es H o F; R5 es H, -NH2, -OH o -CH3; R15 es H, F, CI, -CH3 o -OCH3; R16 es alquilo C1-5; L es -C(O)NH-, -NHC(O)- o -CH2NHC(O)-; A es: como en formula (2) donde: n es 0 o 1; m es 0 o 1; R6 es H o OH y R17 es H, o R6 y R17 forman un enlace puente a través del anillo; R7 está ausente cuando m es 0 y es (-H,-H), =O, (-H,-F) o (-H,-OCH3) cuando m es 1; o R6 y R7, cuando los dos están presentes, junto con los enlaces con los que están unidos, forman un sistema de anillos carbocíclicos o heterocíclicos de tal forma que se forme un sistema heterocíclico bicíclico que contiene nitrogeno; Q es alquilo C1-6, -CH2CF3; -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH(CH3)2, -OCH3, -CH2OCH3 o -CO2CH2CH3, o Q se representa por la formula R8-Y(R9)(R10)R11-Z-(R12)(R13)R14, en la que: R8 es un enlace, -CH2-, -CH2CH2-, o -CO2CH2CH2-; Y es un enlace, H, cicloalquilo C3-7, fenilo, heterociclilo de 5-7 miembros o heteroarilo de 5-6 miembros; R9 no está presente, o R9 es H, F, CI, =O, :::N, -C:::N, -CH2C:::N, -CH2CH2C:::N o alquilo C1-6; R10 no está presente, o R10 es H, F, CI, Br, -NH2, -CH3, -CH2CH3, -CF3, -OH, -OCH3, -OCH(CH3)2, -CH2OCH3, -C(O)NH2, =O, -CO2CH2CH3, -NHCH2CH2OH, -NHCO2CH3, -NHCO2CH2CH3, - NHCO2C(CH3)2CH3, -N(CH3)2 o heteroarilo opcionalmente sustituido con metilo; R11 no está presente o R11 es un enlace, H, -CH2, -NH-, -CH2CH2, -OCH2-, -CO-, -CO2CH2CH2, -C(O)NH-, -C(O)NHCH2-, -C(O)NHCH2CH2-, -NHCO2-, -NHCO2CH2, -NHCO2CH2CH2- o - NHCO2C(CH3)2CH2-; Z no está presente, o Z es un enlace, H, alquilo C1-3, cicloalquilo C3-7, fenilo, heterociclilo de 5-7 miembros o heteroarilo de 5-6 miembros; R12 no está presente, o R12 es H, F, CI, -CH3, -CH2CH3, -OCH3, -CO2CH2CH3, -NHCO2CH3, - NHCO2CH2CH3 o -NHCO2C(CH3)2CH3; R13 no está presente, o R13 es H, F, CI, -CH3, -CH2CH3, -OCH3, -CO2CH2CH3, -NHCO2CH3, -NHCO2CH2CH3 o NHCO2C(CH3)2CH3, R14 no está presente, o R14 es H, =O, -OH, alquilo C1-6, -CH3, -CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, O(CH2)2OH, -CO2CH2CH3, F, CI, Br, :::N, -C:::N, -N(CH3)2, -C(O)CH3, -C(O)NH2, -CH2CH2OH, -C(O)NHCH3, -C(O)N(CH2CH3)2, sulfonilo, alquil (C1-3)-sulfonilo, aminosulfonilo, alquil (C1-3)-aminosulfonilo, 2-metilbutanolilo, 1-metoxi-2-metilbutanilo, 2- metilhex-5-eno-2-ilo, -N(CH3)2, N-etil-N-metiletanaminilo, cicloalquilo de 5-6 miembros, heterociclilo de 5-7 miembros, heteroarilo de 5-6 miembros o fenilo, donde cada sistema cíclico está opcionalmente sustituido con H, -CH3, o -C:::N, y en la que cuando R14 es cicloalquilo, heterociclilo, fenilo o heteroarilo, y cuando Z es un cicloalquilo, heterociclilo, fenilo o heteroarilo, R14 y Z pueden formar un sistema de anillos bicíclicos, y en la que cuando Y es un sistema cíclico y R11 y no está presente, Y y Z pueden formar un sistema de anillos carbocíclicos o heterocíclicos, bicíclicos, saturados, parcialmente insaturados o aromáticos o un sistema de anillos carbocíclicos o heterocíclicos espiro-condensados, saturados, parcialmente insaturados o aromáticos; con la condicion de que el compuesto no sea 4-{[(2-metil-6-fenilpiridin-3-il)carbonil]amino}piperidina-1-carboxilato de etilo.
ARP070105664A 2006-12-19 2007-12-17 Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen. AR064389A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87077706P 2006-12-19 2006-12-19
US89165007P 2007-02-26 2007-02-26

Publications (1)

Publication Number Publication Date
AR064389A1 true AR064389A1 (es) 2009-04-01

Family

ID=39523704

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105664A AR064389A1 (es) 2006-12-19 2007-12-17 Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.

Country Status (10)

Country Link
US (1) US7902373B2 (es)
EP (1) EP2129660A2 (es)
JP (1) JP2010513458A (es)
AR (1) AR064389A1 (es)
CA (1) CA2672373C (es)
CL (1) CL2007003705A1 (es)
PE (1) PE20081385A1 (es)
TW (1) TW200833675A (es)
UY (1) UY30804A1 (es)
WO (1) WO2008075172A2 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2118074B1 (en) 2007-02-01 2014-01-22 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
WO2008104869A1 (en) 2007-02-26 2008-09-04 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
US8440417B2 (en) 2008-05-13 2013-05-14 Cayman Chemical Company, Incorporated Method for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase
US20110306597A1 (en) 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
WO2009153720A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
AP3272A (en) 2008-09-22 2015-05-31 Cayman Chem Co Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases
CN102348412B (zh) * 2009-03-10 2015-05-20 皇家飞利浦电子股份有限公司 哮喘的诊断
WO2010106436A2 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Novel anti-inflammatory agents
DK2486024T3 (en) 2009-10-08 2015-07-27 Sanofi Sa Phenyloxadiazolderivater as pgds inhibitors
DE112010005848B4 (de) 2010-09-06 2016-03-10 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Amidverbindungen
EP2651417B1 (en) * 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
CN103930407B (zh) * 2011-09-12 2019-02-26 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
AR091023A1 (es) * 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
WO2014066568A1 (en) 2012-10-24 2014-05-01 Winthrop-University Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
US10045979B2 (en) * 2014-05-19 2018-08-14 Merial Inc. Anthelmintic compounds
WO2015188085A1 (en) 2014-06-06 2015-12-10 Flexus Biosciences, Inc. Immunoregulatory agents
CA2956163C (en) 2014-07-24 2023-01-10 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
US10081616B2 (en) * 2014-08-28 2018-09-25 X-Chem, Inc. Soluble epoxide hydrolase inhibitors and uses thereof
KR20230026515A (ko) * 2014-09-10 2023-02-24 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
EA201790806A1 (ru) 2014-11-05 2017-11-30 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
BR112017019409A2 (pt) 2015-03-09 2018-04-24 Grace W R & Co forma cristalina de ribosídeo de nicotinamida
LT3277286T (lt) 2015-03-31 2021-07-26 Enanta Pharmaceuticals, Inc. Tulžies rūgšties dariniai kaip fxr/tgr agonistai, ir jų panaudojimo būdai
KR20180095580A (ko) * 2015-12-17 2018-08-27 아스텍스 테라퓨틱스 리미티드 H-pgds 억제제로서의 퀴놀린-3-카르복스아미드
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
JP2019537557A (ja) 2016-10-04 2019-12-26 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒアゴニストとしてのイソキサゾール類似体およびその使用方法
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
CA3066979A1 (en) * 2017-06-13 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
GB201711234D0 (en) 2017-07-12 2017-08-23 Galapagos Nv Pyrrolopyrimidine and pyrrolopyridine derivatives
CN111094988A (zh) 2017-09-13 2020-05-01 普罗根尼蒂公司 先兆子痫生物标志物及相关系统和方法
US11299481B2 (en) 2017-10-20 2022-04-12 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US20210139507A1 (en) 2017-12-13 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h pgds
WO2019126482A1 (en) 2017-12-22 2019-06-27 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
KR20200116945A (ko) * 2018-02-02 2020-10-13 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CA3117943A1 (en) 2018-11-08 2020-05-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
EP3941916A4 (en) 2019-03-20 2022-11-23 Emory University PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES AND RELATED USES THEREOF
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
BR112021024224A2 (pt) 2019-05-31 2022-04-26 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
MX2021014443A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CA3183214A1 (en) 2020-06-19 2021-12-23 Motoaki Baba Condensed ring compounds that inhibit h-pgds
AU2021398540A1 (en) * 2020-12-11 2023-06-22 Intervet International B.V. Anthelmintic compounds comprising a pyridine structure
TW202444703A (zh) 2021-09-14 2024-11-16 美商美國禮來大藥廠 Sstr4促效劑鹽
WO2023113023A1 (ja) 2021-12-17 2023-06-22 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害するアザインドール誘導体
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU706150B2 (en) 1996-04-03 1999-06-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU5530998A (en) 1996-12-18 1998-07-15 E.I. Du Pont De Nemours And Company Relatively stable (1,3-disubstitutedimidazol-2-ylidene)-type carbenes
DE19744401A1 (de) 1997-10-08 1999-04-15 Bayer Ag Verfahren zur Herstellung von Triazolinthion-Derivaten
US6395753B1 (en) 2001-08-30 2002-05-28 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
JP4500483B2 (ja) 2002-03-25 2010-07-14 独立行政法人科学技術振興機構 ヒト由来プロスタグランジン合成酵素阻害剤
JPWO2004006956A1 (ja) 2002-07-12 2005-11-10 独立行政法人科学技術振興機構 脳損傷の予後改善薬とそのスクリーニング方法
JP4550353B2 (ja) 2002-07-24 2010-09-22 株式会社医薬分子設計研究所 造血器型プロスタグランジンｄ２合成酵素阻害剤
CA2503674A1 (en) 2002-10-03 2004-04-15 Institute Of Medicinal Molecular Design, Inc. Quinazolin-4-one derivatives
WO2004056774A2 (en) * 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
WO2004081005A1 (en) 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
DE602004030689D1 (de) 2003-07-23 2011-02-03 Synta Pharmaceuticals Corp Verbindungen gegen entzündungen und immun-relevante verwendungen
AU2005209257A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
PE20070589A1 (es) 2005-10-04 2007-06-22 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Also Published As

Publication number Publication date
CA2672373A1 (en) 2008-06-26
CL2007003705A1 (es) 2008-06-27
PE20081385A1 (es) 2008-10-04
TW200833675A (en) 2008-08-16
EP2129660A2 (en) 2009-12-09
US20080146569A1 (en) 2008-06-19
WO2008075172A2 (en) 2008-06-26
JP2010513458A (ja) 2010-04-30
CA2672373C (en) 2011-08-30
WO2008075172A3 (en) 2008-10-02
US7902373B2 (en) 2011-03-08
UY30804A1 (es) 2008-07-31

Similar Documents

Publication Publication Date Title
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR072171A1 (es) Derivados de nicotinamida, composicion farmaceutica que los comprende y su uso en combinaciones y en la preparacion de un medicamento para el tratamiento del asma.
HRP20180483T1 (hr) Spoj kinolona
AR081653A1 (es) Inhibidores del virus de la hepatitis c
AR059901A1 (es) Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares.
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR082152A1 (es) Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
RS53682B1 (en) PIRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASE
AR038834A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4; composiciones farmaceuticas que los contienen; proceso de preparacion del compuesto y uso del mismo para fabricar un farmaco
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR086977A1 (es) Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR051294A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
RS54708B1 (en) ARYLETINYL DERIVATIVES
AR040351A1 (es) Derivados de quinuclidina-amida, composicion farmaceutica, procedimiento de preparacion del compuesto y su uso para fabricar medicamentos
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
AR048939A1 (es) Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios.
AR083872A1 (es) Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
AR049291A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal